VIRGINIA RETIREMENT SYSTEMS ET Al Takes $1.02 Million Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Virginia Retirement Systems acquired 13,100 shares of Halozyme Therapeutics worth approximately $1.02 million during the second quarter. Institutional investors and hedge funds collectively own 97.79% of the company.
• Analyst sentiment remains positive, with nine Buy ratings, three Holds, and one Sell; Halozyme has a “Moderate Buy” consensus rating and an average price target of $91.20.
• Halozyme exceeded quarterly expectations, reporting $2.28 in EPS and $481 million in revenue, up 47.7% year over year. However, insiders sold 72,478 shares worth about $7.37 million over the past 90 days.

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,100 shares of the biopharmaceutical company's stock, valued at approximately $1,025,000.

Other large investors have also added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC grew its position in Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC lifted its position in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 343 shares in the last quarter. MidFirst Bank acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $28,000. Finally, Quantbot Technologies LP bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $30,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company's stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares of the company's stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 72,478 shares of company stock worth $7,370,004 in the last 90 days. Company insiders own 2.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on HALO shares. Citigroup reaffirmed a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. UBS Group reiterated a "buy" rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Citizens Jmp raised their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research note on Friday, August 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Finally, Benchmark reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $91.20.

Halozyme Therapeutics Price Performance

HALO stock opened at $107.20 on Monday. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The firm has a market capitalization of $12.17 billion, a PE ratio of 32.00, a PEG ratio of 0.41 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $111.15. The business's 50 day simple moving average is $93.73 and its 200 day simple moving average is $77.01.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm's revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.